Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 7,719 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level 2 Clear all
Completed Phase 3 Interventional

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)

NCT05013229
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
IcoSema, Insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
66
States / cities
Guntersville, Alabama • Fresno, California • La Jolla, California + 59 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 21, 2026, 9:51 PM EDT
Completed Phase 4 Interventional

Investigation of the Tolerability of Two Facial Cleansing Routines for Mild to Moderate Acne

NCT05446402
View directory record Official record
Conditions
Acne
Interventions
Geologie Acne Regimen - one side of face, Proactive Acne Regimen - other side of face
Combination Product
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 21, 2026, 9:51 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma

NCT01460602
View directory record Official record
Conditions
Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma
Interventions
MTD of Velcade, Nipent and Rituxan established in Part 1
Drug
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 21, 2026, 9:51 PM EDT
Completed Phase 1 Interventional

Montelukast in Very Low Birthweight Infants

NCT00492102
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Montelukast
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Days and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 21, 2026, 9:51 PM EDT
Active, not recruiting Phase 3 Interventional

Safety and Efficacy of GS-100 Gene Therapy in Patients With NGLY1 Deficiency

NCT06199531
View directory record Official record
Conditions
NGLY1 Deficiency
Interventions
GS-100
Genetic
Lead sponsor
Grace Science, LLC
Industry
Eligibility
2 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
2
States / cities
Oakland, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 21, 2026, 9:51 PM EDT
Recruiting Phase 1 Interventional

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

NCT05172245
View directory record Official record
Conditions
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Carcinoma of Unknown Primary, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma, Locally Advanced Nasal Cavity Squamous Cell Carcinoma, Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma, Locally Advanced Paranasal Sinus Squamous Cell Carcinoma, Locally Advanced Sinonasal Squamous Cell Carcinoma, Maxillary Sinus Squamous Cell Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Sinonasal Cancer AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Sinonasal Cancer AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Sinonasal Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Ipatasertib, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy
Procedure · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Tampa, Florida • Chicago, Illinois • Fairway, Kansas + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 21, 2026, 9:51 PM EDT
Completed Phase 3 Interventional Results available

Tinnitus Retraining Therapy Trial

NCT01177137
View directory record Official record
Conditions
Subjective Tinnitus
Interventions
Conventional sound generator (SG), Placebo sound generator (placebo SG), Standard of Care (SC), Directive Counseling (DC)
Device · Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
6
States / cities
Camp Pendleton, California • San Diego, California • Travis Air Force Base, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2018 · Synced Oct 21, 2026, 9:51 PM EDT
Completed Not applicable Interventional Results available

Ultrasound Guided Adductor Canal Versus Femoral Nerve Blocks for Anterior Cruciate Ligament Reconstruction in Pediatrics

NCT03053401
View directory record Official record
Conditions
Post-operative Pain, Quadriceps Muscle Strength
Interventions
Adductor Canal Block, Femoral Nerve Block, Ultrasound, Stimuplex A needle, local anaesthetic injection, Steroid Drug
Procedure · Device · Drug
Lead sponsor
Akron Children's Hospital
Other
Eligibility
8 Years to 18 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 28, 2020 · Synced Oct 21, 2026, 9:51 PM EDT
Completed Phase 2 Interventional

A Study in People With Abnormal Fat Levels in the Blood

NCT00116519
View directory record Official record
Conditions
Dyslipidemia
Interventions
PPAR alpha, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
54
States / cities
Hoover, Alabama • Fayetteville, Arkansas • San Diego, California + 51 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2007 · Synced Oct 21, 2026, 9:51 PM EDT
Completed Phase 1 Interventional

A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma

NCT00545519
View directory record Official record
Conditions
Relapsed Or Refractory Multiple Myeloma
Interventions
thymoglobulin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 23, 2013 · Synced Oct 21, 2026, 9:51 PM EDT
Completed Phase 2 Interventional Results available

Dose-ranging Study of APD405 in Post-operative Nausea and Vomiting (PONV)

NCT00895830
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
APD405, Placebo
Drug
Lead sponsor
Acacia Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
San Francisco, California • Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2011 · Synced Oct 21, 2026, 9:51 PM EDT
Recruiting Phase 1 Interventional

A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors

NCT07123103
View directory record Official record
Conditions
Solid Tumors
Interventions
XB371
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
Rogers, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 21, 2026, 9:51 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1

NCT04581629
View directory record Official record
Conditions
Autosomal Dominant Hypocalcemia (ADH), Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Interventions
Encaleret
Drug
Lead sponsor
Calcilytix Therapeutics, Inc., a BridgeBio company
Industry
Eligibility
16 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 21, 2026, 9:51 PM EDT
Recruiting Phase 1 Interventional

NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies

NCT07563829
View directory record Official record
Conditions
Metastatic Malignant Neoplasm
Interventions
NPX372
Drug
Lead sponsor
NextPoint Therapeutics, Inc.
Industry
Eligibility
19 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
6
States / cities
La Jolla, California • Baltimore, Maryland • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 21, 2026, 9:51 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Communication Strategies to Increase HPV Vaccinations

NCT06784960
View directory record Official record
Conditions
Papilloma Viral Infection, Vaccine Hesitancy, Communication
Interventions
HPV Message 1, HPV Message 2, HPV Message 3, Control Message, Provider Strong-Recommendation Toolkit
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 45 Years
Enrollment
9,002 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 21, 2026, 9:51 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors

NCT05200559
View directory record Official record
Conditions
Epithelial Ovarian Cancer
Interventions
Pembrolizumab, E7777
Drug
Lead sponsor
Alexander B Olawaiye, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 21, 2026, 9:51 PM EDT
Completed Phase 1 Interventional

Study of CPI-100 in Patients With Advanced Tumors

NCT03781362
View directory record Official record
Conditions
Advanced Tumors
Interventions
CPI-100, Capecitabine
Drug
Lead sponsor
Coordination Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Grand Rapids, Michigan • Cleveland, Ohio • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 21, 2026, 9:51 PM EDT
Completed Phase 2 Interventional Results available

Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer

NCT00666562
View directory record Official record
Conditions
Stage I Bladder Cancer, Stage II Bladder Cancer, Stage III Bladder Cancer
Interventions
Defined Green Tea Catechin Extract, Laboratory Biomarker Analysis, Pharmacological Study, Placebo, Therapeutic Conventional Surgery
Dietary Supplement · Other · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
6
States / cities
Birmingham, Alabama • Burlington, Massachusetts • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 21, 2026, 9:51 PM EDT
Completed Phase 3 Interventional Results available

Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy

NCT00124982
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD), Anti-Tumor Necrosing Factor (TNF) Therapy
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
114
States / cities
Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Oct 21, 2026, 9:51 PM EDT
Completed Not applicable Interventional Results available

Dexmedetomidine Versus Midazolam for Facilitating Extubation

NCT00744380
View directory record Official record
Conditions
Critical Illness
Interventions
Midazolam, Dexmedetomidine
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Oct 21, 2026, 9:51 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Mental Stress & Diesel Exhaust on Cardiovascular Health

NCT03467997
View directory record Official record
Conditions
Blood Pressure, Inflammation, Catecholamines
Interventions
Trier social stress test, Diesel exhaust
Behavioral · Other
Lead sponsor
University of Washington
Other
Eligibility
22 Years to 49 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 21, 2026, 9:51 PM EDT
Completed Phase 1 Interventional

Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma

NCT00580320
View directory record Official record
Conditions
Melanoma, Soft Tissue Sarcoma, Parathyroid Carcinoma, Small Cell Carcinoma of the Lung, Carcinoid Tumors
Interventions
Dacarbazine and bortezomib
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
2
States / cities
Lebanon, New Hampshire • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Oct 21, 2026, 9:51 PM EDT
Recruiting Phase 2 Interventional

tSCS and 5-Azacitidine for Enhanced Motor Outcomes in Cerebral Palsy

NCT07433023
View directory record Official record
Conditions
Cerebral Palsy
Interventions
tSCS, 5-Azacitidine, Mannitol, Functional Activity Training
Other · Drug
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
4 Years to 17 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 21, 2026, 9:51 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain

NCT05803096
View directory record Official record
Conditions
Prostate Disease, Malignancy, Benign Prostatic Hyperplasia, Prostate Cancer, Prostate Adenocarcinoma, Anxiety and Fear, Pain
Interventions
Self-Administered Nitrous Oxide, Oxygen
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 85 Years · Male only
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 21, 2026, 9:51 PM EDT